The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts.

Abstract

A nine-membered panel of experts was asked to determine expert opinions of mortality risks associated with use of low-nitrosamine smokeless tobacco (LN-SLT) marketed for oral use. A modified Delphi approach was employed. For total mortality, the estimated median relative risks for individual users of LN-SLT were 9% and 5% of the risk associated with smoking… (More)

Topics

2 Figures and Tables

Cite this paper

@article{Levy2004TheRR, title={The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts.}, author={David Theodore Levy and Elizabeth A. Mumford and Kenneth Cummings and Elizabeth A. Gilpin and Gary A. Giovino and Andrew Hyland and David T Sweanor and Kenneth E. Warner}, journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}, year={2004}, volume={13 12}, pages={2035-42} }